BOUNDLESS BIO INC

Boundless Bio’s volatile $2.86 stock reflects biotech’s high‑risk, high‑reward reality—market cap, price swings, and investor insights in one snapshot.

Boundless Bio, Inc. is a biotech company pioneering novel cancer therapeutics, targeting oncogene amplified cancers, with a mission to redefine cancer treatment and potentially improve patient outcomes.